NewAmsterdam Pharma’s ESC 2026 data presentations and what they could mean for NAMS stock
NewAmsterdam Pharma (NasdaqGM:NAMS) is in focus after announcing multiple late stage data presentations for its cholesterol drug candidate obicetrapib at the European Society of Cardiology Congress 2026 in Munich, a key cardiology forum.
At a share price of US$25.85, NewAmsterdam Pharma has seen its 30 day share price return fall 6.17% and its year to date share price return decline 26.56%, even though the 3 year total shareholder return of 156.19% points to much stronger longer term momentum.
Seize this moment around NewAmsterdam Pharma’s ESC 2026 spotlight to compare it with 21 high quality undiscovered gems that may be quietly building similar late stage potential in the background.After a sharp pullback despite years of strong total returns, NewAmsterdam Pharma now asks a simple question of investors: Does the current price still reflect an attractive trade off between late stage upside and execution risk?
Preferred Price-to-Book Multiple of 4.9x for NewAmsterdam Pharma: Is it justified?
NewAmsterdam Pharma currently trades at a P/B of 4.9x, which is higher than both similar peers and the broader US Biotechs industry at the last close of $25.85.
The price to book ratio compares a company’s market value to its accounting book value. For a late stage biopharmaceutical group like NewAmsterdam Pharma, which is still unprofitable and investing heavily in drug development, a higher P/B can reflect investor expectations for future revenue from its pipeline rather than current earnings.
Analysts’ forecasts indicate that NewAmsterdam Pharma’s revenue is expected to grow 58.2% per year, compared with 13.1% expected for the US market. At the same time, the company reported revenue of $7.12m and a loss of $259.50m, and losses have increased over the past 5 years. That mix of high forecast growth and ongoing losses can help explain why the market is assigning a P/B of 4.9x even though the company is currently unprofitable.
Compared with similar biotechs, NewAmsterdam Pharma is described as expensive on this metric. Its P/B of 4.9x is higher than the peer average of 4.3x and almost double the US Biotechs industry average of 2.5x. That suggests investors are paying a premium to the sector for the company’s cardiometabolic and Alzheimer’s drug programs, despite its current loss making status.
See what the numbers say about this price and find out in our valuation breakdown. See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-book of 4.9x (OVERVALUED).
However, investors still need to weigh the clinical trial risk around obicetrapib and the impact of ongoing losses of $259.50m on future funding options for NewAmsterdam Pharma.
Find out about the key risks to this NewAmsterdam Pharma narrative.
Another view on NewAmsterdam Pharma’s valuation
The P/B of 4.9x paints NewAmsterdam Pharma as expensive compared with peers, but the SWS DCF model points in the opposite direction. On this view, the stock trading at $25.85 is priced about 76.3% below an estimated fair value of $109.25 and screens as undervalued. Which signal should carry more weight for you?
Look into how the SWS DCF model arrives at its fair value: Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out NewAmsterdam Pharma for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 52 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With mixed signals across NewAmsterdam Pharma’s valuation tools, the sentiment is anything but straightforward. It makes sense to review the data yourself and move quickly if your thesis is clear. To understand what investors see as the key positives, take a closer look at its 3 key rewards.
Looking for more investment ideas beyond NewAmsterdam Pharma?
If NewAmsterdam Pharma has your attention today, do not stop there. Use this moment to refresh your watchlist with other focused, fundamentals based ideas.
- Target resilient balance sheets by scanning companies in the list of solid balance sheet and fundamentals (53 results) that pair financial strength with room for future growth.
- Hunt for quality at a reasonable price by reviewing the 52 high quality undervalued stocks that may offer a more attractive entry point right now.
- Prioritise stability and lower volatility by checking the 79 resilient stocks with low risk scores and avoid missing companies that might help steady your portfolio.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com